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Context: Low levels of nonandrogenic anabolic hormones have been linked with frailty, but evi-
dence is conflicting and prospective data are largely lacking.
Objective: To determine associations between nonandrogenic anabolic hormones and prospective
changes in frailty status.
Design/Setting: A 4.3-year prospective observational study of community-dwelling men participating
in the European Male Ageing Study.
Participants: Men (n = 3369) aged 40 to 79 years from eight European centers.
Main Outcome Measures: Frailty status was determined using frailty phenotype (FP; n = 2114) and
frailty index (FI; n = 2444).
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Analysis: Regression models assessed relationships between baseline levels of insulinlike growth
factor 1 (IGF-1), its binding protein 3 (IGFBP-3), dehydroepiandrosterone sulfate (DHEA-S),
25-hydroxyvitamin D (25OHD), and parathyroid hormone (PTH), with changes in frailty status
(worsening or improving frailty).
Results: The risk of worsening FP and FI decreased with 1 standard deviation higher IGF-1, IGFBP-3,
and 25OHD in models adjusted for age, body mass index, center, and baseline frailty [IGF-1: odds
ratio (OR) for worsening FP, 0.82 (0.73, 0.93), percentage change in FI,23.7% (26.0,21.5); IGFBP-3:
0.84 (0.75, 0.95), 24.2% (26.4,22.0); 25OHD: 0.84 (0.75, 0.95);24.4%, (26.7, 22.0)]. Relationships
between IGF-1 and FI were attenuated after adjusting for IGFBP-3. Higher DHEA-S was associated
with a lower risk ofworsening FP only inmen.70 years old [OR, 0.57 (0.35, 0.92)]. PTHwas unrelated
to change in frailty status.
Conclusions: These longitudinal data confirm the associations between nonandrogenic anabolic
hormones and the changes in frailty status. Interventional studies are needed to establish causality
and determine therapeutic implications. (J Clin Endocrinol Metab 102: 2798–2806, 2017)
F railty describes a state of increased vulnerability tostressors and reduced homeostatic reserve in the elderly
that is associated with adverse outcomes such as loss of
mobility, functional disabilities, dependency, and death (1,
2). With the rapidly aging population, these frailty-related
problems present an increasing challenge to health care
systems worldwide. Better understanding of the underlying
causes and natural history of frailty can enable early
identification of at-risk individuals, development of new
treatments, and instigation of prevention strategies.
The pathophysiology of frailty has been linked with
dysfunctions in multiple physiological systems but the
mechanisms remain poorly understood. Decline in muscle
mass and function is thought tobe central to thedevelopment
of frailty, and because anabolic hormones are one of the key
factors responsible for muscle growth and repair, endocrine
dysregulation has been suggested as a potential etiological
factor for frailty. This is further supportedby clinical sequelae
of various endocrinopathies that share common featureswith
those of frailty in both men and women.
Several studies have investigated associations of ana-
bolic hormones with muscle function and physical per-
formance but relatively few have focused on frailty (3–7).
These studies have been mostly cross-sectional and pro-
spective data are limited. For example, studies of insulinlike
growth factor 1 (IGF-1) have been negative, but resultsmay
have been influenced by low statistical power and over-
adjustment bias (3, 4). Prior results on 25-hydroxyvitamin
D (25OHD)havealsobeen conflicting (3, 5, 8, 9), and studies
focusing on dehydroepiandrosterone sulfate (DHEA-S)
have been underpowered (10, 11). The results of studies
examining the associations between testosterone and
frailty are largely inconsistent (12, 13); we have explored
the relationship between testosterone and frailty in our
population and the findings are presented separately.
In this study, we hypothesized that nonandrogenic
anabolic hormone levels would be related to changes in
frailty status. Using the population-based European Male
Ageing Study (EMAS), we sought to determine prospective
associations between a number of nonandrogenic anabolic
hormones and changes in frailty status.
Methods
Subjects
The subjects were participants in the EMAS, the details of
which have been described previously (14). Briefly, 3369 men
aged 40 to 79 were recruited between 2003 and 2005 from
population-based sampling frames in eight European centers.
The participants completed a series of questionnaires, anthro-
pometric measurements, and physical and cognitive func-
tional assessments, and a fasting blood sample was collected.
Ethical approval was obtained in accordance with the local
requirements.
Participants were recontacted after a minimum of 4 years
(median, 4.3 years); the methods of data collection at follow-up
were the same as in the baseline study. During the follow-up
period, 193 (6%) men died and 440 (13%) were lost to fol-
low-up.
The longitudinal analysis was restricted to men with com-
plete frailty data at baseline and follow-up. We excluded par-
ticipants with self-reported adrenal or pituitary disease or the
use of medications affecting the somatotrophic axis (dopamine
agonist, recombinant human growth hormone, somatostatin
analog), parathyroid hormone (PTH)/25OHD levels (vitamin
D and/or calcium supplements/analogs), or DHEA-S levels
(DHEA-S supplements).
Assessment of hormone predictors
A fasting morning (before 10:00 AM) venous blood sample
was used for all hormonemeasurements as previously described
(6, 15) (see Supplemental Data for details).
Clinical assessments
Participants were asked about lifestyle, general health, and
comorbidities. The interviewer-assisted questionnaire included
the Medical Outcomes Study 36-item short form survey (16),
the Physical Activity Scale for the Elderly (17), Beck Depression
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Inventory (18), and International Prostate Symptoms Score
(19). Physical function was assessed by the Reuben Physical
Performance Test (20) and the Tinetti balance and postural
stability index (21). The Rey–Osterrieth Complex Figure test
(22), the Camden Topographical Recognition Memory test
(23), and the Digit-Symbol Substitution test (24) were used to
assess cognitive function. We assessed height, weight, waist
circumference, middle upper arm and calf circumferences, and
skin-fold thickness at several body sites.
Assessment of frailty
Frailty was characterized by the two widely used approaches:
frailty phenotype (FP) and frailty index (FI).
The EMAS FP was first developed in 2011 as an adaptation
from the Cardiovascular Health Study (2) andwas based on five
criteria: sarcopenia, exhaustion, slowness, weakness, and low
activity (see Supplemental Table 1 for details). Individuals with
three ormore criteria were classed as frail, those with one or two
criteria as prefrail, and those with none as robust. The EMAS FP
has been internally validated by showing that it predicts adverse
health outcomes, including falls and death (25).
The EMAS FI comprises 39 health deficits (symptoms and
signs, functional and cognitive impairments; Supplemental
Table 2) known to accumulate with age and associated with
adverse health outcomes. The deficit variables were derived
from the Medical Outcomes Study 36-item short form survey
and Beck Depression Inventory questionnaires, physical per-
formance and cognitive tests, and self-reported comorbidities
(20–23). The EMAS FI was created using a standardized pro-
cedure (26) and calculated as a ratio of deficits present to the
total number of possible deficits. Binary variables were coded
as 0 or 1 (absent/present), and intermediate responses (e.g.,
sometimes/maybe) were coded as 0.5. Continuous variables
were dichotomized based on the distribution of participants’
scores; cut-points were set at the worst performing 10th centile.
Individuals with .20% missing data were excluded.
Statistical analysis
Descriptive statistics are presented as the mean 6 standard
deviation (SD) or n (%), and statistical significance of between-
group differences was assessed using analysis of variance.
Frailty phenotype models
Change in frailty was defined using transitions in frailty states
between baseline and follow-up. The transitions considered were:
worsening frailty (robust or prefrail at baseline progressing to
prefrail or frail at follow-up; referent category, persistent robust
and persistent prefrail) and improving frailty (prefrail or frail at
baseline transitioning to robust or prefrail state at follow-up;
referent category, persistent frail and prefrail).
Logistic regressionmodels determined relationships between
an individual predictor (hormone at baseline) and outcome
(transition in frailty state). Each potential endocrine predictor
was considered as an untransformed value standardized as a
z score [(raw score – mean)/SD] to allow comparison of results
between endocrine predictors with different units of measure-
ment. We adjusted all models for baseline frailty to account for
the heterogeneity of baseline frailty status. Models were then
further adjusted for variables significantly correlated with the
hormonal predictors, such as age and body mass index (BMI),
and center. In further analyses, the effects of additional
adjustments for other potential confounders, such as smoking,
alcohol use, education, physical activity, diabetes and cardio-
vascular disease (CVD), and other hormones were also ex-
plored. Additionally, all analyses in which PTH and 25OHD
were the main predictor variables were adjusted for 25OHD
and PTH levels, respectively. The results were displayed as odds
ratios (OR) with 95% confidence intervals (CIs) for change in
frailty status associated with a 1 SD difference in baseline
hormone level.
FI models
In view of the right skewing of the FI variable, relationships
between baseline hormone level and FI at follow-up were
assessed using a negative binomial regression. The FI variable
was converted to a 0- to 39-count scale where “0” represented
no deficits and “39” represented the maximum number of
deficits. Analyses were serially adjusted for baseline FI (model
1), age (model 2), center (model 3), and BMI (model 4). As
earlier, endocrine predictors were standardized as z scores. The
results were presented as percentage change (95% CI) in FI
associated with a 1 SD difference in baseline hormone level
(negative values indicating improving frailty and positive values
indicating worsening frailty during follow-up).
To assess for potential effect of age on the relationships between
hormones and frailty, we performed an exploratory analysis in-
troducing an interaction term (baseline hormone 3 age category)
to the fully adjusted model. The “age category” represented four
age bands: 40 to 49, 50 to 59, 60 to 69, and 70 to 79 years.
All analyses were performed using Stata 13 SE software
(StataCorp, College Station, TX).
Results
Of the 3369 men who participated in EMAS, 2444 men
remained in the FI analysis and 2114 in the FP analysis after
excluding those with known pituitary or adrenal disease
(n=29), relevantmedicationuse (n=47),missingFI (n=556)
or FP (n = 226) data, and failure to show up for follow-up
assessment (n = 623) (Supplemental Fig. 1). Comparedwith
the main analytical sample, men lost to follow-up (n = 435)
were older and had a higher prevalence of smoking, de-
pression, diabetes, and frailty at baseline (Supplemental
Tables 3 and 4). This was the case also for the men who
died (n = 188), with addition of a higher systolic blood
pressure, creatinine, and waist-to-hip ratio in this group
when compared with the analytical sample.
Worsening frailty
Of 1589menwhowere robust at baseline, 390 became
prefrail and 20 became frail at follow-up. Among 505
men who were prefrail at baseline, 49 progressed to
frailty. Therefore, in total, 459 men presented with
worsening frailty at follow-up (Supplemental Fig. 2).
Improving frailty
One hundred ninety-two men who were prefrail and
twowhowere frail at baseline became robust at follow-up.
2800 Swiecicka et al Nonandrogenic Anabolic Hormones Predict Frailty J Clin Endocrinol Metab, August 2017, 102(8):2798–2806
Additionally, 12 men who were frail at baseline transi-
tioned to the prefrail state at follow-up. Therefore, in total,
an improvement in frailty status was observed in 206 men
(Supplemental Fig. 2).
Population characteristics
Baseline characteristics are shown in Table 1. The men
had a mean age of 59 years and a mean BMI of 28 kg/m2.
Six percent were known to suffer from diabetes, 21%
from depression, and 33% reported a history of CVD.
Twenty percent admitted current smoking.
Comparedwithmenwhodid not experience any change
in frailty status, men whose frailty status deteriorated were
older (61 vs 57 years), were less active physically, had lower
BMI, and had a higher prevalence of diabetes and CVD
(Table 2). Their baseline levels of DHEA-S, IGF-1, and its
binding globulin 3 (IGFBP-3) were significantly lower than
those whose frailty status remained stable.
Men whose frailty status improved were younger (59 vs
64years) andhadhigher diastolic bloodpressure anda lower
prevalence ofCVDwhen comparedwithmenwho remained
prefrail or frail throughout the study period (Table 2).
Baseline levels of anabolic hormones were numerically
higher in men who experienced improvement in frailty, al-
though the differences were not statistically significant.
Hormonal predictors of worsening frailty
Higher baseline levels of IGF-1 and IGFBP-3 were
associated with a lower likelihood of worsening frailty
status as assessed by FP and FI in baseline frailty–adjusted
models with and without additional adjustment for age,
BMI, and center (Tables 3 and 4, models 1 through 4).
When the IGF-1 analysis was also adjusted for IGFBP-3,
IGF-1 was no longer associated with lower risk of
worsening FI (Supplemental Table 5). Similarly, IGFBP-3
was no longer an independent predictor of FI and FP after
adjustment for IGF-1.
Higher DHEA-S levels were associated with lower risk
of worsening frailty status as assessed by both FP and FI
(Tables 3 and 4). However, statistical significance was
lost after adjusting for age in both analyses.
Baseline PTH was unrelated to change in frailty status
in any model (Tables 3 and 4).
Higher 25OHD levelswere associatedwith lower risk of
worsening frailty status as assessed by FI and FP (Tables 3
and 4). Although the relationship between 25OHD level
and FP was not significant in the models adjusted for
baseline frailty and age, the point estimate for the OR was
similar to that in the fully adjusted model (0.92 vs 0.84,
Table 4). Further adjustment of the models for other pu-
tative confounders that were not components of FI or FP
but correlated with endocrine predictors—such as smok-
ing, alcohol use, education, physical activity, diabetes,
CVD, testosterone, and estradiol—did not alter the results.
Hormonal predictors of improving frailty phenotype
Higher baseline levels of IGFBP-3 were associated with a
greater probability of improving frailty phenotype in only
the model adjusted for baseline frailty status (Table 5). This
relationship became nonsignificant after adjusting for age.
Higher vitamin D levels were associated with greater
probability of improved frailty in baseline frailty–, age-,
center-, and BMI-adjusted models (Table 5). This relation-
ship, however, was rendered nonsignificant following ad-
justment for the presence of diabetes (SupplementalTable 7).
Interaction with age
In a secondary analysis, there was evidence of age-
related differences in the relationships between DHEA-S
and worsening FP. In men aged .70 years, higher
baseline DHEA-S levels were associated with a lower
risk of worsening FP [OR, 0.57 (0.35, 0.92), P = 0.021],
but this relationship was not observed in younger men
(P value for interaction of 0.001). The association in older
men remained significant after further adjustment for
depression score and diabetes. There were no significant
age-related interactions in the relationships between
other hormones and change in FP or FI (not shown).
Discussion
Our study has shown robust longitudinal multivariable-
adjusted relationships between higher baseline levels of






Age, y 59 6 11
BMI, kg/m2 28 6 4
WHR 0.98 6 0.06
Waist circumference, cm 98 6 11
Smoking, n (%) 474 (20%)
Frequent alcohol use, n (%) 561 (23%)
Below degree education 1731 (71%)
Systolic BP, mm Hg 146 6 20
Diastolic BP, mm Hg 87 6 12
Creatinine, mmol/L 92 6 28
PASE score 202 6 89
Severe depression (BDI bands 4–6), n (%) 82 (4%)
Mild depression (BDI bands 2–3), n (%) 398 (17%)
CVD 702 (33%)
Diabetes, n (%) 153 (6%)
DHEA-S, mmol/L 4.6 6 2.7
PTH, pg/mL 28.3 6 14.2
25OHD, ng/mL 25.9 6 12.9
IGF-1, mg/L 135 6 42.8
IGFBP-3, mg/mL 4.5 6 1.0
Abbreviations: BDI, Beck Depression Inventory score, BP, blood pressure;
PASE, Physical Activity Scale for the Elderly; WHR, waist-to-hip ratio.
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IGF-1, IGFBP-3, and vitamin D and lower 4-year risks
of worsening frailty status in middle-aged and older
community-dwelling European men. In models adjusted
for baseline frailty status, higher levels of DHEA-S were
associated with lower risk of worsening frailty status but
statistical significance was lost on age adjustment.We also
showed that baseline PTH was unrelated to changes in
frailty status in any model. Importantly, the associations
between hormone levels and frailty showed consistency
regardless of whether frailty was assessed by FP or FI.
These data highlight potential mechanisms of frailty and
identify possible modifiable targets for intervention.
Comparison with prior studies, including
mechanistic explanations
IGF-1 and IGFBP-3
Our findings contrast with the results from the lon-
gitudinal study of Yeap et al. (4) of 1484 men .70 years
of age that showed no significant multivariable-adjusted
relationship between IGF-1 and IGFBP-3 and incident
frailty as assessed by questionnaire. Consistent with
our data, Yeap et al. did show significant univariate
associations between higher IGF-1 and IGFBP-3 levels
and lower risks for incident frailty. However, statistical
significance was lost after adjusting for age, BMI,
smoking, diabetes, and fasting status. This loss of sig-
nificance could perhaps be explained by covariates such
as BMI being on the causal pathway linking hormone
levels to frailty. However, when we also adjusted for
baseline levels of BMI, diabetes, and depression, higher
levels IGF-1 and IGFBP-3 were still significantly related
to a lower risk of frailty progression (Supplemental Ta-
bles 5 and 6). Therefore, overadjustment bias cannot fully
explain the discrepant results. It seems likely that sample
size, the restricted and older age range (.70 years), and
the quartile modeling strategy adopted by Yeap et al. (4)
may have limited the statistical power to show signifi-
cant relationships. Our study adds important data by
assessing frailty through clinical objective assessments
(not simply questionnaires) based on validated methods,
in a larger cohort, over awider age range and in a younger
group capturing earlier frailty transitions and having a
lower risk of “healthy survivor” bias.
Similarly, our results contrast with those from a study
of 1271 men and women .65 years of age who were
Table 2. Baseline Parameters Stratified by Frailty Transition Group, as Assessed by Frailty Phenotype Derived














N 459 1443 206 270
Age, y 61 6 11 57 6 10 ,0.001 59 6 10 64 6 10 ,0.001
BMI, kg/m2 27.3 6 4.0 27.7 6 4.0 0.029 27.7 6 4.2 27.2 6 5.0 0.105
WHR 0.98 6 0.06 0.98 6 0.06 0.309 0.99 6 0.06 0.98 6 0.07 0.856
Waist circumference, cm 98.1 6 10.8 97.9 6 10.7 0.857 99 6 11.6 98.4 6 13.1 0.59
Smoking, n (%) 101 (22) 271 (19) 0.252 45 (22) 63 (23) 0.517
Frequent alcohol use, n (%) 116 (25) 333 (23) 0.341 50 (24) 56 (21) 0.515
Below degree education,
n (%)
329 (72) 1014 (70) 0.564 157 (76) 204 (76) 0.868
Systolic BP, mm Hg 145 6 20 145 6 20 0.735 145 6 22 148 6 23 0.138
Diastolic BP, mm Hg 87 6 11 87 6 12 0.46 89 6 13 86 6 12 0.023
Creatinine, mmol/L 91 6 17 92 6 33 0.988 90 6 17 92 6 17 0.209
PASE score 188 6 82 214 6 87 ,0.001 156 6 93 139 6 92 0.049
Severe depression (BDI
bands 4–6), n (%)
8 (2) 35 (2) 0.112 10 (5) 21 (8) 0.247
Mild depression (BDI bands
2–3), n (%)
83 (18) 212 (15) 0.214 49 (24) 74 (37) 0.267
CVD, n (%) 178 (29) 281 (22) 0.001 79 (38) 127 (48) 0.033
Diabetes, n (%) 38 (8) 69 (5) 0.013 11 (5) 24 (9) 0.321
DHEA-S, mmol/L 4.5 6 2.8 4.8 6 2.7 0.005 4.4 6 2.4 4.0 6 2.7 0.008
PTH, pg/mL 28.7 6 12.8 28.1 6 14.9 0.208 30.0 6 14.9 29.3 6 11.8 0.779
25OHD, ng/mL 25.5 6 13.8 26.2 6 12.7 0.066 25.8 6 13.4 24.1 6 13.0 0.117
IGF-1, mg/L 128.86 38.9 138.5 6 44.2 ,0.001 131.2642.8 128.4 6 46.2 0.267
IGFBP-3, mg/mL 4.4 6 1.0 4.6 6 1.0 ,0.001 4.4 6 1.1 4.3 6 1.0 0.068
Data are expressed as mean 6 SD for continuous variables or as number (percentage) for binary categorical variables. P values were calculated using
baseline parameters and using analysis of variance.
Abbreviations: BDI, Beck Depression Inventory score; BP, blood pressure; PASE, Physical Activity Scale for the Elderly; WHR, waist-to-hip ratio.
aRobust or prefrail men at baseline progressing to prefrail or frail state at follow-up.
bPrefrail or frail men at baseline transitioning to robust or prefrail state at follow-up.
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participants in the Longitudinal Aging Study Amsterdam
(3). In that study, the significance of the univariate re-
lationship between lower IGF-1 levels and a higher risk
for incident frailty was lost after adjusting for age, sex,
medication, obesity, physical activity, and chronic dis-
ease. The lack of significance in fully adjustedmodelsmay
have been explained by limited statistical power and
overadjustment but may also have been influenced by the
use of a nonvalidated measure of frailty and the absence
of a sex-stratified analysis.
Our results are biologically plausible in light of pre-
vious research, highlighting the central role of IGF-1 in
mediating muscle growth and repair across the lifespan
(27). Despite well-documented effects of IGF-1 onmuscle
physiology in animal models, human studies have dem-
onstrated conflicting results concerning associations of
IGF-1 with muscle mass and physical performance (28,
29). One possible reason for these conflicting results
might be the largely overlooked role of IGF binding
proteins in mediating the bioavailability of IGF-1. We
have studied the biologically most important IGF binding
protein in humans, IGFBP-3. This is bound to IGF-1 in a
complex that not only serves to extend the half-life of
IGF-1 but also acts as an IGF-1 reservoir. IGFBP-3 is also
thought to exert independent growth factor properties on
cells as well as potentiate the effects of IGF-1 (30). In our
analysis, the relationship between IGF-1 and frailty was
largely attenuated by IGFBP-3 adjustment, suggesting a
likely mediating rather than confounding role of IGFBP-3
in the IGF-1/frailty association.
Vitamin D
Our group (6) and others (3, 31) have described sig-
nificant cross-sectional relationships between low vita-
min D and frailty in the general population. For example,
the InCHIANTI study showed that the risk of prevalent
frailty was fourfold higher in men with low vitamin
D levels compared with men with normal levels (5). In the
present study, the largest prospective study reported to
date, we report strong multivariable-adjusted relation-
ships between higher levels of vitaminD level and reduced
risk of frailty progression.
Several smaller studies have assessed the prospective
relationship between vitamin D and incident frailty/
reduced physical performance and have generated dif-
fering results, some positive (8, 32) and some negative
Table 4. Multivariable-Adjusted OR (95% CI) for Worsening Frailty Phenotype Associated With Baseline
Hormonal Predictor: Models and Adjustments
Baseline Parameter N
Model 1: Baseline Frailty
Model 2: Baseline Frailty
and Age
Model 3: Baseline Frailty,
Age, and Center
Model 4: Baseline Frailty,
Age, Center, and BMI
OR 95% CI P Value OR 95% CI P Value OR 95% CI P Value OR 95% CI P Value
IGF-1 1885 0.77 0.68, 0.86 ,0.001 0.85 0.75, 0.96 0.008 0.82 0.73, 0.93 0.002 0.82 0.73, 0.93 0.002
IGFBP-3 1888 0.81 0.73, 0.90 ,0.001 0.90 0.80, 1.01 0.070 0.84 0.74, 0.94 0.003 0.84 0.75, 0.95 0.006
DHEA-S 1891 0.87 0.78, 0.97 0.012 1.07 0.95, 1.22 0.259 1.07 0.94, 1.21 0.299 1.06 0.93, 1.20 0.390
PTHa 1890 1.05 0.95, 1.16 0.329 1.03 0.93, 1.14 0.588 1.00 0.90, 1.12 0.938 1.01 0.90, 1.13 0.860
25OHDb 1828 0.92 0.83, 1.03 0.162 0.89 0.80, 1.00 0.053 0.86 0.76, 0.97 0.013 0.84 0.75, 0.95 0.007
aModels 3 and 4 additionally adjusted for baseline 25OHD level.
bModels 3 and 4 additionally adjusted for baseline PTH level.








Frailty, Age, and Center
Model 4: Baseline























IGF-1 2426 27.2 29.3, 25.0 ,0.001 24.1 26.2, 21.7 0.001 23.7 26.0, 21.5 0.001 23.7 26.0, 21.5 0.001
IGFBP-3 2428 28.2 210.5, 25.8 ,0.001 24.8 26.9, 22.6 ,0.001 23.5 25.7, 21.4 0.002 24.2 26.4, 22.0 ,0.001
DHEA-S 2428 26.0 28.2, 23.6 ,0.001 1.0 21.5, 3.7 0.437 20.1 22.7, 2.4 0.917 0.2 22.3, 2.8 0.852
PTHb 2429 2.2 0.1, 4.5 0.059 1.3 20.8, 3.6 0.230 1.3 20.8, 3.6 0.231 0.9 21.2, 3.1 0.402
25OHDc 2347 23.3 25.6, 21.0 0.006 24.7 26.9, 22.5 ,0.001 24.7 27.0, 22.4 ,0.001 24.4 26.7, 22.0 ,0.001
aChange (% change/4 years) in FI per SD increase in anabolic hormone level. Negative% changemeans that the baseline hormone level is associatedwith
improvement of frailty status, whereas positive % change means that the hormone is associated with worsening of frailty status.
bModels 3and 4 additionally adjusted for baseline 25OHD level.
cModels 3 and 4 additionally adjusted for baseline PTH level.
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(9, 33). Comparison between studies is limited particu-
larly because of the different frailty definitions adopted
and marked variation in modeling strategy, including
covariate adjustment.
The largest of these prior studies involved 1267
community-dwelling men in which baseline vitamin D
level did not predict incident frailty defined by the Fried
FP criteria (9). The analysis was adjusted for a large
number of confounders and the predictor (vitamin D
level) was not considered as a continuous variable, which
might have adversely affected the statistical power.
There are several potential mechanisms throughwhich
low vitamin D levels could contribute to frailty. Low
vitamin D levels have been linked to altered muscle
protein synthesis, decreased muscle strength, sarcopenia,
worsening physical performance, and falls (34). These
effects of low vitamin D on muscle are thought to be
partially mediated by raised proinflammatory cytokines
such as interleukin (IL)-12 and IL-2 (5, 34). Low vitamin
D could also contribute to frailty indirectly through
secondary hyperparathyroidism. In our analysis, how-
ever, adjustment for PTH level did not appear to alter the
nature of the relationship between 25OHD and frailty.
Our prospective data are also supported by results of
clinical trials and meta-analyses that indicate beneficial
effects of vitamin D supplementation on muscle function,
especially in older individuals with vitamin D deficiency
(35). However, no trials to date have reported the effects
of vitamin D therapy on the development of frailty.
PTH
This hormone has potential mechanistic links to frailty
because it has been implicated in the development of
neuromuscular dysfunction and has effects on muscle
protein turnover and energy metabolism (36). The direct
relationship of PTH with frailty has been explored in a
small number of cross-sectional studies but, to the best of
our knowledge, there have been no prior prospective
studies. One prospective study reported an association of
higher PTH levels with acceleratedmuscle loss, which can
contribute to frailty (37).
We previously reported a significant cross-sectional
association of baseline PTH level and prevalent frailty,
which persisted following multiple adjustments including
vitaminD (6). Shardell et al. (5) reported that elevated PTH
was strongly associated with all individual components of
the FP in elderly men, except low activity levels.
We now showed that baseline PTH was unrelated to
change in frailty status in multiple adjusted models.
However, in view of the strong potential mechanistic ar-
guments, additional prospective studies may be valuable to
further assess the relationship between PTH and frailty.
DHEA-S
We found that higher baseline DHEA-S levels were
associated with a lower risk of worsening frailty. This
association became nonsignificant after adjusting for age,
BMI, and center, except for men older than 70 years, in
whom higher DHEA-S level remained predictive of lower
risk of frailty progression in a fully adjusted model.
Only two small studies (n = 254 and n = 416) have
previously reported relationships betweenDHEA-S levels
and incident frailty (10, 11). Both studies enrolled elderly
community-based men and showed similar relationships
to our study. Our data confirm these previous findings
in a much larger cohort of middle-aged and elderly men.
Several potential pathways could link low DHEA-S with
frailty. DHEA-S may have an anabolic effect on skeletal
muscles, which has been suggested to be age-dependent and
vary across lifespan (38) and, more recently, immunomod-
ulatory andneuroprotective effects of this hormonehave been
described (39).However, results ofDHEA-S supplementation
in nonfrail adults have been disappointing and there is in-
sufficient evidence to support the use of DHEA-S in the frail.
Strengths and limitations
Our studyhas several important strengths,which include
(1) use of a well-defined, longitudinal, community-based
Table 5. Multivariable-Adjusted OR (95% CI) for Improving Frailty Phenotype Associated With Baseline
Hormonal Predictor: Models and Adjustments
Baseline Parameter N
Model 1: Baseline Frailty
Model 2: Baseline Frailty
and Age
Model 3: Baseline Frailty,
Age, and Center
Model 4: Baseline Frailty,
Age, Center, and BMI
OR 95% CI P Value OR 95% CI P Value OR 95% CI P Value OR 95% CI P Value
IGF-1 471 1.08 0.91, 1.29 0.377 0.96 0.79, 1.15 0.643 0.94 0.78, 1.15 0.555 0.94 0.77, 1.14 0.539
IGFBP-3 471 1.21 1.00, 1.46 0.049 1.06 0.87, 1.29 0.579 1.04 0.85, 1.28 0.686 1.02 0.83, 1.25 0.863
DHEA-S 471 1.19 0.98, 1.45 0.072 0.91 0.73, 1.13 0.396 0.94 0.75, 1.17 0.589 0.95 0.76, 1.18 0.640
PTHa 472 1.03 0.84, 1.26 0.775 1.08 0.87, 1.33 0.476 1.09 0.87, 1.37 0.452 1.08 0.86, 1.36 0.481
25OHDb 459 1.14 0.94, 1.37 0.172 1.18 0.97, 1.44 0.099 1.25 0.99, 1.56 0.051 1.27 1.01, 1.58 0.039
aModels 3 and 4 additionally adjusted for baseline 25OHD level.
bModels 3 and 4 additionally adjusted for baseline PTH level.
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multicenter cohort, (2) a large sample size with adequate
power to provide conclusive results, (3) use of standardized
methods to assess hormone levels, and (4) use of two well-
validated frailty models providing internally consistent
results. We acknowledge some limitations, including the
response rate for participation at baseline, which was 41%.
Although this is comparable to other large epidemiological
studies, the prevalence of frailty at baseline might have been
overestimated or underestimated through selection. Addi-
tionally, 435 men were lost to follow-up and therefore the
true incidence of frailty has probably been underestimated.
Because this would tend to bias the results toward the null,
the reported strength of our associations is likely to be
conservative. Finally, our analysis is based on the results of
single hormone measurements that do not capture pulsatile
hormone variation and could attenuate regression coeffi-
cients to the null through regression dilution bias.
Conclusion
We showed significant longitudinal age-adjusted re-
lationships between higher levels of IGF-1, IGFBP-3, and
vitamin D and lower risks of worsening frailty in men. In
unadjusted analyses, we also showed that higher levels of
DHEA-S were associated with lower risk of worsening
frailty. These robust findings from a large well-characterized
community-based cohort enhance our understanding of the
etiology of frailty and suggest potential for therapeutic in-
terventions that could shape new treatment strategies and
public health policies aimed at increasing health span, in-
dependence, and well-being in older age.
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